Recent advances in islet transplantation using highly purified islets and effective immunosuppression strategies have resulted in substantial improvement in achieving insulin independence in type 1 diabetes patients. However, there are side effects from long-term immunosuppression, and transplant rejection and/or the recurrence of autoimmune attack of the transplanted islets cannot be completely prevented, even with immunosuppressive treatment. Therefore, construction of a safe and functional bioartificial pancreas (BAP) that provides an adequate environment for islet cells may be an important approach to treat diabetic patients. Various types of BAP devices have been developed and examined in animals. In this review, I introduce the previous BAP studies and our approach of BAP development.
ArcherJ.; KayeR.; MutterG.Control of streptozocine diabetes in Chinese hamsters by cultured mouse islet cells without immunosuppression: A preliminary report.J. Surg. Res.28: 77–85; 1980.
4.
AssadyS.; MaorG.; AmitM.; Itskovitz-EldorJ.; SkoreckiK. L.; TzukermanM.Insulin production by human embryonic stem cells.Diabetes50: 1691–1697; 2001.
5.
BalamuruganA. N.; GuY.; TabataY.; MiyamotoM.; CuiW.; HoriH.; SatakeA.; NagataN.; WangW.; InoueK.Bioartificial pancreas transplantation at prevascularized intermuscular space: Effect of angiogenesis induction on islet survival.Pancreas26: 279–285; 2003.
6.
BallingerW. F.; LacyP. E.Transplantation of intact pancreatic islets in rats.Surgery72: 175–186; 1972.
7.
ChickW. L.; LikeA. A.; LaurisV.Beta cell culture on synthetic capillaries: an artificial endocrine pancreas.Science187: 847–849; 1975.
DufourJ. M.; RajotteR. V.; ZimmermanM.; RezaniaA.; KinT.; DixonD. E.; KorbuttG. S.Development of an ectopic site for islet transplantation using biodegradable scaffolds.Tissue Eng.11: 1323–1331; 2005.
10.
Duvivier-KaliV. F.; OmerA.; ParentR. J.; O'NeilJ. J.; WeirG. C.Complete protection of islets against allorejection and autoimmunity by a simple barium-alginete membrane.Diabetes50: 1698–1705; 2001.
11.
EuvrardS.; UlrichC.; LefrancoisN.Immunosuppressants and skin cancer in transplant patients: Focus on rapamycin.Dermatol. Surg.30: 628–633; 2004.
12.
EvansM. G.; WarnockG. L.; RajotteR. V.Comparison of sites for transplantation of canine pancreatic microfragments.Diabetes Res.10: 35–41; 1989.
13.
HesseU. J.; SutherlandD. E.; GoresP. F.; Sitges-SerraA.; NajarianJ. S.Comparison of splenic and renal sub-capsular islet autografting in dogs.Transplantation41: 271–274; 1986.
KempC. B.; KnightM. J.; ScharpD. W.; LacyP. E.; BallingerW. F.Transplantation of isolated pancreatic islets into the portal vein of diabetic rats.Nature244: 447; 1973.
22.
KobayashiN.; FujiwaraT.; WestermanK. A.; InoueY.; SakaguchiM.; NoguchiH.; MiyazakiM.; CaiJ.; TanakaN.; FoxI. J.; LeboulchP.Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes.Science287: 1258–1262; 2000.
23.
KobayashiT.; AomatsuY.; IwataH.; KinT.; KanehiroH.; HisanagaM.; KoS.; NagaoM.; NakajimaY.Indefinite islet protection from autoimmune destruction in nonobese diabetic mice by agarose microencapsulation without immunosuppression.Transplantation75: 619–625; 2003.
24.
Kogan-LibermanD.; BurroughsM.; EmreS.; MosconaA.; ShneiderB. L.The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.J. Pediatr. Gastroenterol. Nutr.33: 445–449; 2001.
25.
LacyP. E.; HegreO. D.; Gerasimidi-VazeouA.; GentileF. T.; DionneK. E.Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets.Science254: 1782–1784; 1991.
26.
LanzaR. P.; BorlandK. M.; LodgeP.; CarrettaM.; SullivanS. J.; MullerT. E.; SolomonB. A.; MakiT.; MonacoA. P.; ChickW. L.Treatment of severely diabetic pancreatectomized dogs using a diffusion-based hybrid pancreas.Diabetes41: 886–889; 1992.
27.
LanzaR. P.; ButlerD. H.; BorlandK. M.; StarukJ. E.; FaustmanD. L.; SolomonB. A.; MullerT. E.; RuppR. G.; MakiT.; MonacoA. P.; ChickW. L.Xenotrans-plantation of canine, bovine, and porcine islets in diabetic rats without immunosuppression.Proc. Natl. Acad. Sci. USA88: 11100–11104; 1991.
28.
LanzaR. P.; ChickW.Transplantation of encapsulated cell and tissues.Surgery121: 1–9; 1997.
29.
LimF.; SunA. M.Microencapsulated islets as bioartificial endocrine pancreas.Science210: 908–910; 1980.
30.
LumelskyN.; BlondelO.; LaengP.; VelascoI.; RavinR.; McKayR.Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets.Science292: 1389–1394; 2001.
31.
MakiT.; OtsuI.; O'NeilJ. J.; DunleavyK.; MullonC. J.; SolomonB. A.; MonacoA. P.Treatment of diabetes by xenogenic islets without immunosuppression.Use of a vascularized bioartificial pancreas. Diabetes45: 342–347; 1996.
32.
MikiA.; Rivas-CarrilloJ. D.; Navarro-AlvarezN.; Soto-GutierrezA.; ChenY.; TanakaK.; NarushimaM.; TabataY.; OkitsuT.; NoguchiH.; MatsumotoS.; TanakaN.; KobayashiN.Maintenance of neovascularization at the implantation site of an artificial device by bFGF and endothelial cell transplant.Cell Transplant.15: 893–901; 2006.
33.
NarushimaM.; KobayashiN.; OkitsuT.; TanakaY.; LiS. A.; ChenY.; MikiA.; TanakaK.; NakajiS.; TakeiK.; Soto-GutierrezA.; Rivas-CarrilloJ. D.; Navarro-AlvarezN.; JunH. S.; WestermanK. A.; NoguchiH.; LakeyJ. R.; LeboulchP.; TanakaN.; YoonJ. W.A human beta-cell line for transplantation therapy to control type 1 diabetes.Nat. Biotechnol.23: 1274–1282; 2005.
34.
OhgawaraH.; HirotaniS.; MiyazakiJ.; TeraokaS.Membrane immunoisolation of a diffusion chamber for bioartificial pancreas.Artif. Organs22: 788–794; 1998.
35.
OmerA.; Duvivier-KaliV. F.; TrivediN.; WilmotK.; Bonner-WeirS.; WeirG. C.Survival and maturation of microencapsulated porcine neonatal pancreatic cell clusters transplanted into immunocompetent diabetic mice.Diabetes52: 69–75; 2003.
36.
SakuraiT.; SatakeA.; SumiS.; InoueK.; NagataN.; TabataY.; MiyakoshiJ.The efficient prevascularization induced by fibroblast growth factor 2 with a collagen-coated device improves the cell survival of a bioartificial pancreas.Pancreas28: e70–e79; 2004.
37.
ShapiroA. M.; LakeyJ. R.; RyanE. A.; KorbuttG. S.; TothE.; WarnockG. L.; KnetemanN. M.; RajotteR. V.Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.N. Engl. J. Med.343: 230–238; 2000.
38.
Soon-ShiongP.; HeintzR. E.; MeridethN.; YaoQ. X.; YaoZ.; ZhengT.; MurphyM.; MoloneyM. K.; SchmehlM.; HarrisM.; MendezR.; MendezR.; SandfordP. A.Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation.Lancet343: 950–951; 1994.
SunA. M.; ParisiusW.; HealyG. M.; VacekI.; MacmorineH. G.The use, in diabetic rats and monkeys of artificial capillary units containing cultured islets of Langerhans (artificial endocrine pancreas).Diabetes26: 1136–1139; 1977.
41.
The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N. Engl. J. Med.329: 977–986; 1993.
42.
The Diabetes Control and Complications Trial Research Group.Adverse events and their association with treatment regimens in the diabetes control and complications trial.Diabetes Care18: 1415–1427; 1995.
43.
TzeW. J.; WongF. C.; ChenL. M.; O'YoungS.Implantable artificial endocrine pancreas unit used to restore normoglycemia in the diabetic rat.Nature264: 466–467; 1976.
44.
WangW.; GuY.; TabataY.; MiyamotoM.; HoriH.; NagataN.; ToumaM.; BalamuruganA. N.; KawakamiY.; NozawaM.; InoueK.Reversal of diabetes in mice by xenotransplantation of a bioartificial pancreas in a prevascularized subcutaneous site.Transplantation73: 122–129; 2002.
45.
ZekornT.; SiebersU.; HorcherA.; SchnettlerR.; KlockG.; BretzelR. G.; ZimmermannU.; FederlinK.Barium-alginate beads for immunoisolated transplantation of islets of Langerhans.Transplant. Proc.24: 937–939; 1992.
